Immunohistochemical investigation of BRAF p.V600E mutations in thyroid carcinoma using 2 separate BRAF antibodies

Applied Immunohistochemistry and Molecular Morphology

Volumn 22, Issue 8, 2014, Pages 562-567

  Fisher, Kevin E ^a   Neill, Stewart G ^a   Ehsani, Laleh ^a   Caltharp, Shelley A ^a   Siddiqui, Momin T ^a   Cohen, Cynthia ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRAF p.V600E; Cancer; Clone EP152Y; Clone VE1; Immunohistochemistry; Molecular; Thyroid

Indexed keywords

B RAF KINASE; MONOCLONAL ANTIBODY; MUT BRAF ANTIBODY; PAN BRAF ANTIBODY; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; PRIMER DNA;

ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FALSE POSITIVE RESULT; FINE NEEDLE ASPIRATION BIOPSY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PREDICTIVE VALUE; PYROSEQUENCING; SENSITIVITY AND SPECIFICITY; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; THYROID NEOPLASMS;

BASE SEQUENCE; DNA PRIMERS; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

EID: 84912574021     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3182a2f75f     Document Type: Article

References (16)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Lloyd R, Buehler D, Khanafshar E. Papillary thyroid carcinoma variants. Head Neck Pathol. 2011;5:51-56.
3. Rowe LR, Bentz BG, Bentz JS. Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis. J Clin Pathol. 2007;60:1211-1215.
4. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399-5404.
5. Lanzilotta SG, Grammatica L, Paradiso A, et al. BRAF in papillary thyroid carcinoma. Cell Oncol. 2007;29:269-277.
6. Poulikakos PI, Rosen N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell. 2011;19:11-15.
7. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011;122:11-19.
8. Kondo T, Nakazawa T, Murata S, et al. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. Hum Pathol. 2007;38:1810-1818.
9. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19: 1167-1214.
10. Melck AL, Yip L, Carty SE. The utility of BRAF testing in the management of papillary thyroid cancer. Oncologist. 2010;15:1285-1293.
11. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309:1493-1501.
12. Lade-Keller J, Rømer KM, Guldberg P, et al. Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas. J Mol Diagn. 2013;15:70-80.
13. Baitei EY, Zou M, Al-Mohanna F, et al. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma. J Pathol. 2009;217:707-715.
14. Capper D, Voigt A, Bozukova G, et al. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSIH colorectal cancer. Int J Cancer. 2013;133:1624-1630.
15. Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol. 2013;37:61-65.
16. Preusser M, Capper D, Berghoff AS, et al. Expression of BRAF V600E mutant protein in epithelial ovarian tumors. Appl Immunohistochem Mol Morphol. 2013;21:159-164.